AstraZeneca PLC – one of a few remaining big pharmas investing in antibiotics R&D – is giving up its late-stage small molecule antibiotics portfolio to Pfizer Inc. The two drug makers announced a deal Aug. 24, whereby AstraZeneca will sell commercialization and development rights to its commercial and late-stage small molecule antibiotics business in most markets outside the US to Pfizer in exchange for $550m upfront plus a delayed $175m payment in 2019 and regulatory and sales milestones.
Pfizer plans to include the programs in its Essential Health portfolio, the area of its business that includes generic drugs...








